Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ANTACIDS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ANTACIDS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ANTACIDS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 VALUE CHAIN ANALYSIS
14 HEALTHCARE ECONOMY
14.1 HEALTHCARE EXPENDITURE
14.2 CAPITAL EXPENDITURE
14.3 CAPEX TRENDS
14.4 CAPEX ALLOCATION
14.5 FUNDING SOURCES
14.6 INDUSTRY BENCHMARKS
14.7 GDP RATION IN OVERALL GDP
14.8 HEALTHCARE SYSTEM STRUCTURE
14.9 GOVERNMENT POLICIES
14.1 ECONOMIC DEVELOPMENT
15 PIPELINE ANALYSIS
15.1 PHASE III CANDIDATES
15.2 PHASE II CANDIDATES
15.3 PHASE I CANDIDATES
15.4 OTHERS (PRE-CLINICAL AND RESEARCH)
16 GLOBAL ANTACIDS MARKET, BY TYPE
16.1 OVERVIEW
16.2 SYSTEMIC ANTACIDS
16.2.1 BY DOSAGE FORM
16.2.1.1. TABLETS
16.2.1.2. LIQUID
16.2.1.3. CHEWABLE GUMMIES
16.2.1.4. SUSPENSION
16.2.1.5. OTHERS
16.2.2 BY COMPOSISTION
16.2.2.1. ALUMINIUM HYDROXIDE
16.2.2.2. CALCIUM CARBONATE
16.2.2.3. MAGNESIUM HYDROXIDE
16.2.2.4. MAGNESIUM CARBONATE
16.2.2.5. MAGNESIUM TRISILICATE
16.2.2.6. SODIUM BICARBONATE
16.2.2.7. COMBINATION DRUGS
16.2.2.8. OTHERS
16.3 NONSYSTEMIC ANTACIDS
16.3.1 BY DOSAGE FORM
16.3.1.1. TABLETS
16.3.1.2. LIQUID
16.3.1.3. CHEWABLE GUMMIES
16.3.1.4. SUSPENSION
16.3.1.5. OTHERS
16.3.2 BY COMPOSISTION
16.3.2.1. ALUMINIUM HYDROXIDE
16.3.2.2. CALCIUM CARBONATE
16.3.2.3. MAGNESIUM HYDROXIDE
16.3.2.4. MAGNESIUM CARBONATE
16.3.2.5. MAGNESIUM TRISILICATE
16.3.2.6. SODIUM BICARBONATE
16.3.2.7. COMBINATION DRUGS
16.3.2.8. OTHERS
16.4 COMPLEX ANTACIDS
16.4.1 BY DOSAGE FORM
16.4.1.1. TABLETS
16.4.1.2. LIQUID
16.4.1.3. CHEWABLE GUMMIES
16.4.1.4. SUSPENSION
16.4.1.5. OTHERS
16.4.2 BY COMPOSISTION
16.4.2.1. ALUMINIUM HYDROXIDE
16.4.2.2. CALCIUM CARBONATE
16.4.2.3. MAGNESIUM HYDROXIDE
16.4.2.4. MAGNESIUM CARBONATE
16.4.2.5. MAGNESIUM TRISILICATE
16.4.2.6. SODIUM BICARBONATE
16.4.2.7. COMBINATION DRUGS
16.4.2.8. OTHERS
17 GLOBAL ANTACIDS MARKET, BY COMPOSITION
17.1 OVERVIEW
17.2 ALUMINIUM HYDROXIDE
17.3 CALCIUM CARBONATE
17.4 MAGNESIUM HYDROXIDE
17.5 MAGNESIUM CARBONATE
17.6 MAGNESIUM TRISILICATE
17.7 SODIUM BICARBONATE
17.8 COMBINATION DRUGS
17.9 OTHERS
18 GLOBAL ANTACIDS MARKET, BY DOSAGE FORM
18.1 OVERVIEW
18.2 TABLETS
18.3 LIQUID
18.4 CHEWABLE
18.4.1 CHEWABLE GUMMIES
18.4.2 CHEWABLE TABLETS
18.5 EFFERVESCENT
18.6 SUSPENSION
18.7 GEL
18.8 OTHERS
19 GLOBAL ANTACIDS MARKET, BY FLAVOUR
19.1 OVERVIEW
19.2 MINT
19.3 FRUITS
19.4 CITRUS
19.5 HONEY
19.6 UNFLAVOURED
19.7 OTHERS
20 GLOBAL ANTACIDS MARKET, BY DRUG TYPE
20.1 OVERVIEW
20.2 GENERICS
20.3 BRANDED
20.3.1 ALKA-SELTZER
20.3.2 MAALOX
20.3.3 MYLANTA
20.3.4 ROLAIDS
20.3.5 TUMS
20.3.6 NEUT
20.3.7 OTHERS
21 GLOBAL ANTACIDS MARKET, BY INDICATION
21.1 OVERVIEW
21.2 GASTROESOPHAGEAL REFLUX DISEASE
21.2.1 SYSTEMIC ANTACIDS
21.2.2 NONSYSTEMIC ANTACIDS
21.2.3 COMPLEX ANTACIDS
21.3 HEARTBURN
21.3.1 SYSTEMIC ANTACIDS
21.3.2 NONSYSTEMIC ANTACIDS
21.3.3 COMPLEX ANTACIDS
21.4 INDIGESTION
21.4.1 SYSTEMIC ANTACIDS
21.4.2 NONSYSTEMIC ANTACIDS
21.4.3 COMPLEX ANTACIDS
21.5 STOMACH ULCER
21.5.1 SYSTEMIC ANTACIDS
21.5.2 NONSYSTEMIC ANTACIDS
21.5.3 COMPLEX ANTACIDS
21.6 NON-ULCER DYSPEPSIA
21.6.1 SYSTEMIC ANTACIDS
21.6.2 NONSYSTEMIC ANTACIDS
21.6.3 COMPLEX ANTACIDS
21.7 URINARY ALKALINIZATION
21.7.1 SYSTEMIC ANTACIDS
21.7.2 NONSYSTEMIC ANTACIDS
21.7.3 COMPLEX ANTACIDS
21.8 GAS AND BLOATING
21.8.1 SYSTEMIC ANTACIDS
21.8.2 NONSYSTEMIC ANTACIDS
21.8.3 COMPLEX ANTACIDS
21.9 OSTEOPOROSIS
21.9.1 SYSTEMIC ANTACIDS
21.9.2 NONSYSTEMIC ANTACIDS
21.9.3 COMPLEX ANTACIDS
21.1 OTHERS
22 GLOBAL ANTACIDS MARKET, BY AGE GROUP
22.1 OVERVIEW
22.2 ADULT
22.3 PEDIATRIC
22.4 GERIARTIC
23 GLOBAL ANTACIDS MARKET, BY GENDER
23.1 OVERVIEW
23.2 MALE
23.3 FEMALE
24 GLOBAL ANTACIDS MARKET, BY END USER
24.1 OVERVIEW
24.2 HOSPITALS
24.2.1 PRIVATE
24.2.2 PUBLIC
24.3 SPECIALTY CLINICS
24.4 HOME HEALTHCARE
24.5 OTHERS
25 GLOBAL ANTACIDS MARKET, BY DISTRIBUTION CHANNEL
25.1 OVERVIEW
25.2 DIRECT TENDER
25.3 RETAIL SALES
25.3.1 HOSPITAL PHARMACIES
25.3.2 DRUGS STORES
25.3.3 ONLINE PHARMACIES
25.3.4 OTHERS
25.4 OTHERS
26 GLOBAL ANTACIDS MARKET, COMPANY LANDSCAPE
26.1 COMPANY SHARE ANALYSIS: GLOBAL
26.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
26.3 COMPANY SHARE ANALYSIS: EUROPE
26.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
26.5 MERGERS & ACQUISITIONS
26.6 NEW PRODUCT DEVELOPMENT & APPROVALS
26.7 EXPANSIONS
26.8 REGULATORY CHANGES
26.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
27 GLOBAL ANTACIDS MARKET, BY GEOGRAPHY
27.1 MCNEIL CONSUMER PHARMACEUTICALS CO (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC)
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 SWISS CHEM HEALTHCARE
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 GLAXOSMITHKLINE PLC
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 BIOZENTA LIFESCIENCE PVT. LTD
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 SUN PHARMACEUTICAL INDUSTRIES LTD
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 PFIZER INC.
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 SPI PHARMA
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 ASTRAZENECA
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 BAYER AG
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 SANOFI
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 RECKITT BENCKISER GROUP PLC.
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 PHARMACEUTICAL ASSOCIATES INC.
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 ALLEGIANT HEALTH
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 HUBLORE HEALTHCARE PVT LTD
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 UNIBIOTECH FORMULATIONS
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 LUPIN
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 CIPLA
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 ZOIC PHARMACEUTICALS
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
